13F Holdings
中文EN

INTS INTENSITY THERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1567264 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.6%
TTM EPS YoY90.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-161.8%
ROA-121.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets25.6%
Debt / equity0.00x
Current ratio3.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-29.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue————
R&D expense$6.79M$10.50M$4.79M$5.13M
SG&A expense$5.19M$6.09M$3.53M$2.42M
Operating income-$11.97M-$16.59M-$8.32M-$7.55M
Interest expense—$0$305,000$82,000
Income tax$0$0$0$0
Net income-$11.61M-$16.27M-$10.54M-$7.58M
EPS (basic)-8.56-29.24-1.38-2.22
EPS (diluted)-8.56-29.24-1.38-2.22
Weighted avg. shares (diluted)1.36M556,2798.62M3.41M
Balance sheet
Cash & equivalents$11.92M$2.59M$8.56M$1.31M
Current assets$12.71M$3.36M$15.46M$1.45M
Total assets$14.10M$4.78M$17.30M$1.76M
Current liabilities$2.15M$1.75M$3.96M$6.82M
Total liabilities$2.23M$1.86M$4.13M$6.86M
Shareholders' equity$11.88M$2.92M$13.16M-$15.10M
Shares outstanding2.52M604,91513.71M3.41M
Cash flow statement
Operating cash flow-$9.23M-$15.22M-$7.21M-$5.48M
Investing cash flow$0$6.35M-$6.02M$0
Financing cash flow$18.56M$2.90M$20.47M$2.25M
Stock-based compensation$2.00M$3.07M$1.40M$1.17M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.